Human Anti-Oxidation Protein A1M—A Potential Kidney Protection Agent in Peptide Receptor Radionuclide Therapy

Peptide receptor radionuclide therapy (PRRT) has been in clinical use for 15 years to treat metastatic neuroendocrine tumors. PRRT is limited by reabsorption and retention of the administered radiolabeled somatostatin analogues in the proximal tubule. Consequently, it is essential to develop and emp...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahlstedt, Jonas, Tran, Thuy A., Strand, Sven-Erik, Gram, Magnus, Åkerström, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4691176/
https://www.ncbi.nlm.nih.gov/pubmed/26694383
http://dx.doi.org/10.3390/ijms161226234

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4691176/
https://www.ncbi.nlm.nih.gov/pubmed/26694383
http://dx.doi.org/10.3390/ijms161226234

Ejemplares similares